Compare · DYN vs LLY
DYN vs LLY
Side-by-side comparison of Dyne Therapeutics Inc. (DYN) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DYN and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.09T, about 233.0x DYN ($4.69B).
- LLY has been more active in the news (16 items in the past 4 weeks vs 15 for DYN).
- LLY has more recent analyst coverage (25 ratings vs 22 for DYN).
- Company
- Dyne Therapeutics Inc.
- Eli Lilly and Company
- Price
- -
- -
- Market cap
- $4.69B
- $1.09T
- 1M return
- -0.57%
- -
- 1Y return
- +86.00%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 15
- 16
- Recent ratings
- 22
- 25
Dyne Therapeutics Inc.
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest DYN
- Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Director Rhodes Jason P sold $65,184,894 worth of shares (2,586,928 units at $25.20) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Commercial Officer Friedl-Naderer Johanna sold $5,939 worth of shares (226 units at $26.28) as part of a pre-agreed trading plan, decreasing direct ownership by 0.15% to 153,982 units (SEC Form 4) to satisfy withholding tax
- Chief Medical Officer Kerr Douglas sold $40,892 worth of shares (1,556 units at $26.28) as part of a pre-agreed trading plan, decreasing direct ownership by 0.92% to 167,599 units (SEC Form 4) to satisfy withholding tax
- CEO & President Cox John sold $131,032 worth of shares (4,986 units at $26.28) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 363,165 units (SEC Form 4) to satisfy withholding tax
- Chief Financial Officer Lucera Erick sold $47,225 worth of shares (1,797 units at $26.28) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 119,766 units (SEC Form 4) to satisfy withholding obligation
- SEC Form 144 filed by Dyne Therapeutics Inc.
- SEC Form 144 filed by Dyne Therapeutics Inc.
- SEC Form 144 filed by Dyne Therapeutics Inc.
- SEC Form 144 filed by Dyne Therapeutics Inc.
Latest LLY
- Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference
- New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity
- Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases
- FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
- Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.14% to 3,004 units (SEC Form 4)
- Director Luciano Juan R was granted 13 shares, increasing direct ownership by 0.08% to 16,918 units (SEC Form 4)
- Director Fyrwald J Erik was granted 8 shares, increasing direct ownership by 0.01% to 75,418 units (SEC Form 4)
- Director Alvarez Ralph was granted 10 shares, increasing direct ownership by 0.02% to 55,745 units (SEC Form 4)